Knowledge of your GLP1R and GIPR variants should be interpreted with a qualified healthcare provider to contextualize baseline cardiovascular risk, expected metabolic response, and monitoring intensity
As a result, individual differences in metabolism, age, genetics, health, prescription drug usage, absorption rate or other factors are taken into consideration
We conducted comprehensive few-shot learning experiments to assess data efficiency using varying numbers of training samples per class (2, 8, 32, 64, 96, and 128 shots)
Zhou Q, Yang L, Wang Q, Li Y, Wei C, Xie L
Average starting weights were 222.4 lbs for 10 mg, 219.6 lbs for 15 mg, and 224.2 lbs for placebo
Ranibizumab may be a reasonable treatment alternative to consider for patients with severe NPDR or non-high-risk PDR who can follow-up regularly